Astrazeneca Ab

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Astazeneca Ab

Dizal Pharmaceutical Co., Limited

Qibin Su

Jason Grant Kettle

Sameer Pralhad Kawatkar

Melissa Vasbinder

Claudio Edmundo Chuaqui

Neil Patrick Grimster

James Francis McCabe

Magnus K Nilsson

Linette Ruston

Annika Birgitta Margareta Astrand

Jon James Winter-Holt

Richard Donald Woessner

Anna Ingrid Kristina Berggren

Johan R Johansson

Bernard Barlaam

Matti Juhani Lepistö

Matti Juhani Lepisto

Dedong Wu

Karl Magnus Nilsson

Frederick Woolf Goldberg

Wenzhan Yang

Sudhir Mahadeo Hande

Avipsa Ghosh

Michael Steven Bodnarchuk

Annika Birgitta Margareta ÅStrand

Annika Astrand

James Mccabe

Annika Birgitta Margareta Åstrand

Phillip Lichtor

Kun Song

James Sheppeck

Reem Telmesani

Tudor Grecu

Sameer Kawatkar

Linette Lys Ruston

Melissa Marie Vasbinder

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

2,6,9-trisubstituted purines

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R-Rhave any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

JAK1 selective inhibitors

Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein

Compounds and methods for inhibiting JAK

Growing community of inventors

Waltham, MA, United States of America

Qibin Su